Welcome to the all-new Vetlearn

  • Vetlearn is becoming part of NAVC VetFolio.
    Starting in January 2015, Compendium and
    Veterinary Technician articles will be available on
    NAVC VetFolio. VetFolio subscribers will have
    access to not only the journals, but also:
  • Over 500 hours of CE
  • Community forums to discuss tough cases
    and networking with your peers
  • Three years of select NAVC Conference
    Proceedings
  • Free webinars for the entire healthcare team

To access Vetlearn, you must first sign in or register.

registernow

  Sign up now for:
Become a Member

Reference Desk June 2012

Merial Launches PUREVAX® Recombinant FeLV Vaccine

    New molecular technology provides improved potency

    DULUTH, Georgia, June 22, 2012—Merial’s PUREVAX® Recombinant FeLV, the newest addition to its line of non-adjuvanted feline vaccines, is now available. Delivered subcutaneously by needle injection, PUREVAX Recombinant FeLV features improved potency, providing excellent protection with a lower antigen concentration than PUREVAX Recombinant Leukemia Vaccine.

    Feline leukemia virus (FeLV) can lead to contagious, incurable and lethal disease.  FeLV causes cancer in about 20% of infected cats  and contributes to the development of other infectious diseases and anemia by suppressing the immune system and function of bone marrow. The American Association of Feline Practitioners (AAFP) recommends FeLV vaccination for all kittens,  and an annual booster inoculation is recommended for cats considered to be at risk of exposure which include those not housed strictly indoors.

    “PUREVAX Recombinant FeLV offers the convenience of subcutaneous delivery with the efficacy and safety you would expect from a non-adjuvanted recombinant vaccine,” said Robert Menardi, DVM, marketing director for Pet Vaccines, Merial. “Non-adjuvanted vaccines may help reduce the potential risks associated with adjuvants, which include injection site reaction, injection site granuloma or chronic inflammation.”

    About PUREVAX
    Merial developed PUREVAX Recombinant FeLV in response to customer desire for a safe, efficacious, non-adjuvanted product with convenient route of administration. PUREVAX Recombinant FeLV uses recombinant canarypox-vectored vaccine technology, which stimulates FeLV-specific cell-mediated immunity and is proven effective in the face of severe challenge.

    PUREVAX Recombinant FeLV is recommended for the vaccination of healthy cats 8 weeks or older as an aid in the prevention of disease due to feline leukemia virus. For primary vaccination, cats should receive two 1-ml dose vaccinations, three weeks apart. Annual booster injections are recommended in cats considered to be at risk of exposure. Diagnostic testing for FeLV prior to vaccination also is recommended.

    About Merial
    Merial is a world-leading, innovation-driven animal health company, providing a comprehensive range of products to enhance the health, well-being and performance of a wide range of animals. Merial employs approximately 5,600 people and operates in more than 150 countries worldwide. Its 2011 sales were more than $2.8 billion. Merial is a Sanofi company. For more information, visit www.merial.com.

    Source: Merial

    didyouknow

    Did you know... In feline upper respiratory disease, differential diagnosis includes viral, bacterial, and fungal infections; foreign bodies; tooth root disease; neoplasia; and inflammatory polyps.Read More

    These Care Guides are written to help your clients understand common conditions. They are formatted to print and give to your clients for their information.

    Stay on top of all our latest content — sign up for the Vetlearn newsletters.
    • More
    Subscribe